Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.

The perioperative treatment landscape for muscle-invasive bladder cancer is changing rapidly with the emergence of immune checkpoint inhibitor- and antibody-drug conjugate-based strategies. Trials such as NIAGARA, EV-304/KEYNOTE-B15, and EV-303/KEYNOTE-905 have shown substantial improvements in event-free survival, ove...

Masanao Shinohara, T. Narita, T. Hamaya et al. · 1 citation
Open access Sep 2026

Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy

We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).

Keiichiro Miyajima, T. Yanagisawa, Wataru Fukuokaya et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.